Zepbound vs Ozempic Head-to-Head Efficacy: What the Clinical Data Actually Shows

What Makes Tirzepatide and Semaglutide Mechanistically Different

Tirzepatide and semaglutide both activate the GLP-1 receptor, but that is where the overlap ends. Semaglutide is a selective GLP-1 receptor agonist approved at 0.5 to 2.0 mg weekly as Ozempic for type 2 diabetes (T2D) and at 2.4 mg weekly as Wegovy for obesity. Tirzepatide, marketed as Mounjaro for T2D and Zepbound for obesity, is a single peptide that activates both GLP-1 and GIP receptors simultaneously, a design that appears to amplify insulin secretion and appetite suppression beyond what GLP-1 alone achieves.

GLP-1 Receptor Action

GLP-1 receptor activation slows gastric emptying, suppresses glucagon, and reduces appetite via hypothalamic signaling. Semaglutide's 94% sequence homology to native GLP-1, combined with an albumin-binding fatty acid chain, gives it a half-life of roughly seven days, enabling once-weekly dosing. The pharmacology is well-characterized in FDA labeling and published receptor-binding studies. 1

The GIP Co-Agonism Difference

GIP (glucose-dependent insulinotropic polypeptide) was long considered a "failed" incretin target because early GIP agonists produced only modest effects in isolation. Tirzepatide's engineered peptide appears to sensitize GIP receptors in adipose tissue and the central nervous system, an effect described in a 2023 Cell Metabolism mechanistic review. 2 The practical result in Phase 3 data: larger caloric deficits, greater fat-mass reduction, and stronger dose-dependent weight loss than any approved semaglutide dose has produced in a matched population.

Why the Mechanism Comparison Matters for Dosing

Ozempic's approved range tops out at 2.0 mg weekly in the U.S. For T2D. Zepbound's approved range tops out at 15 mg weekly for obesity. Comparing 15 mg tirzepatide to 1 mg semaglutide is comparing near-maximum to mid-range doses, which complicates cross-trial interpretation significantly. Readers should keep that dose asymmetry in mind throughout this article.

SURMOUNT-1 vs STEP-1: The Best Available Weight-Loss Comparison

No single randomized controlled trial has put tirzepatide and semaglutide at their respective obesity doses into the same protocol head-to-head. The best available evidence comes from indirect comparison of SURMOUNT-1 and STEP-1, two Phase 3 trials with similar enrollment criteria, primary endpoints, and follow-up durations.

SURMOUNT-1 Results (Tirzepatide)

SURMOUNT-1 enrolled 2,539 adults without diabetes with BMI ≥30 kg/m² (or ≥27 with a weight-related comorbidity) and randomized them to tirzepatide 5 mg, 10 mg, or 15 mg vs placebo once weekly for 72 weeks. Published in the New England Journal of Medicine in 2022, the trial reported mean weight losses of 15.0%, 19.5%, and 20.9% for the 5 mg, 10 mg, and 15 mg doses respectively, against 3.1% for placebo. 3 At 15 mg, 91% of participants achieved ≥5% weight loss, and 57% achieved ≥20% weight loss, a threshold rarely reached with any prior pharmacotherapy.

STEP-1 Results (Semaglutide 2.4 mg)

STEP-1 enrolled 1,961 adults without diabetes with BMI ≥30 kg/m² (or ≥27 with a comorbidity) and randomized them to semaglutide 2.4 mg once weekly vs placebo for 68 weeks. Mean weight loss in the semaglutide group was 14.9% vs 2.4% for placebo (P<0.001). 4 Roughly 86% of participants achieved ≥5% weight loss, and 32% achieved ≥20%.

Indirect Comparison Limitations

SURMOUNT-1 ran 4 weeks longer than STEP-1. Baseline BMI differed slightly (38.0 vs 37.9 kg/m²). Placebo arms were not identical in absolute weight loss. A 2023 network meta-analysis in Diabetes, Obesity and Metabolism used adjusted indirect comparison and estimated tirzepatide 15 mg produces approximately 6 to 8 percentage points more mean weight loss than semaglutide 2.4 mg, but the confidence intervals overlapped at lower tirzepatide doses. 5 That is a meaningful but not definitive signal.

SURPASS-2: The Only Randomized Head-to-Head Data Available

SURPASS-2 is the closest thing to a direct comparison trial, though it studied T2D patients rather than people with obesity alone, and it compared tirzepatide to semaglutide 1 mg, not 2 mg or Zepbound doses.

Trial Design

SURPASS-2 enrolled 1,879 adults with T2D inadequately controlled on metformin and randomized them to tirzepatide 5 mg, 10 mg, or 15 mg or semaglutide 1 mg weekly for 40 weeks. The primary endpoint was change in HbA1c from baseline.

Glycemic Outcomes

All three tirzepatide doses outperformed semaglutide 1 mg on HbA1c reduction. The 15 mg tirzepatide arm reduced HbA1c by a mean of 2.58 percentage points vs 1.86 percentage points for semaglutide 1 mg (P<0.001). 6 Even the lowest tirzepatide dose (5 mg, mean reduction 2.09%) beat semaglutide 1 mg.

Weight Outcomes in SURPASS-2

Weight loss in SURPASS-2 showed a similar pattern. Tirzepatide 5 mg, 10 mg, and 15 mg produced mean weight reductions of 7.6 kg, 9.3 kg, and 11.2 kg respectively, vs 5.7 kg for semaglutide 1 mg. 6 These differences occurred in a T2D population on a background of metformin, so they likely underestimate what either drug would produce in a non-diabetic population at full obesity doses.

The Semaglutide 1 mg Ceiling

SURPASS-2 used semaglutide 1 mg, not the 2.0 mg Ozempic dose or the 2.4 mg Wegovy dose. A subsequent analysis in Lancet Diabetes and Endocrinology estimated that if the comparator had been semaglutide 2 mg, the weight-loss gap between arms would have narrowed but not closed. 7 This is a key caveat when reading any claim that tirzepatide is categorically superior.

SUSTAIN-7: Semaglutide's T2D Weight Data in Context

SUSTAIN-7 compared semaglutide 0.5 mg and 1.0 mg to dulaglutide 0.75 mg and 1.5 mg in 1,201 people with T2D over 40 weeks and is frequently cited as a benchmark for semaglutide's weight effect at Ozempic doses.

SUSTAIN-7 Weight Loss Figures

At semaglutide 1.0 mg, mean weight loss was 6.5 kg over 40 weeks (roughly 6.8% from a mean baseline of 95.6 kg). At 0.5 mg, mean weight loss was 4.5 kg. 8 Both figures are substantially below the 5.7 kg at 40 weeks seen in SURPASS-2's semaglutide 1 mg arm, a difference likely explained by the higher baseline BMI in SURPASS-2's population.

Contextualizing SUSTAIN-7 Against Tirzepatide

Tirzepatide was not available when SUSTAIN-7 ran. Placing SUSTAIN-7's semaglutide 1 mg figure (6.5 kg at 40 weeks) next to SURMOUNT-1's tirzepatide 15 mg figure (22.0 kg at 72 weeks) makes tirzepatide appear overwhelmingly superior, but that comparison conflates T2D vs obesity populations, different follow-up durations, and near-maximum vs mid-range dosing. A fair interpretation acknowledges all three variables.

Cardiovascular Outcomes: Where Semaglutide Has More Evidence

Cardiovascular outcomes data represent the single strongest area where semaglutide's evidence base is more mature than tirzepatide's as of mid-2025.

SELECT Trial (Semaglutide)

SELECT enrolled 17,604 adults with established cardiovascular disease and overweight or obesity but without diabetes and randomized them to semaglutide 2.4 mg or placebo. Published in the New England Journal of Medicine in November 2023, SELECT showed a 20% relative reduction in major adverse cardiovascular events (MACE) over a mean follow-up of 39.8 months (HR 0.80, 95% CI 0.72 to 0.90, P<0.001). 9 This is the trial behind the FDA's expanded semaglutide label for cardiovascular risk reduction.

SURPASS-CVOT and SURMOUNT-MMO (Tirzepatide)

Tirzepatide's dedicated cardiovascular outcomes trial, SURMOUNT-MMO, is enrolling as of 2025, and top-line results have not yet been published. SURPASS-CVOT assessed non-inferiority of tirzepatide vs dulaglutide in T2D and found tirzepatide non-inferior (HR 0.85, 95% CI 0.71 to 1.02) but the trial was not powered for superiority and was conducted in T2D rather than in a pure obesity-with-CVD population. 10 Until SURMOUNT-MMO reports, prescribers who are treating patients primarily to reduce cardiovascular risk have stronger trial-level support for semaglutide.

Blood Pressure and Lipids

Both drugs reduce systolic blood pressure by approximately 3 to 6 mmHg and improve LDL and triglyceride levels in a roughly weight-proportional manner. A 2024 meta-analysis in the Journal of the American Heart Association found no statistically significant difference between tirzepatide and semaglutide on blood pressure reduction after adjusting for weight lost. 11

Glycemic Control: Which Drug Works Harder for Type 2 Diabetes

Both drugs are FDA-approved for T2D. For glycemic control, the SURPASS trial program, eight Phase 3 trials, consistently showed tirzepatide reducing HbA1c by 1.8 to 2.58 percentage points across doses, often reaching normal glucose levels in a substantial proportion of participants.

HbA1c Reduction Across Programs

The American Diabetes Association's 2024 Standards of Care note that tirzepatide "demonstrated greater reductions in HbA1c compared with injectable semaglutide 1 mg in a head-to-head trial." 12 Semaglutide 1 mg typically reduces HbA1c by 1.4 to 1.9 percentage points in its Phase 3 program, a range that still represents clinically meaningful control but falls short of tirzepatide's top-end performance.

Rates of Normal Glucose

In SURPASS-2, 31% of participants on tirzepatide 15 mg achieved an HbA1c <5.7% (normal range) at week 40, vs 2% on semaglutide 1 mg. 6 No prior T2D drug had moved so many participants to normoglycemia in a Phase 3 trial.

Sleep Apnea

SURMOUNT-2 included a substudy in patients with T2D and obesity where tirzepatide 10 mg and 15 mg reduced apnea-hypopnea index by 29 to 51%, and a dedicated SURMOUNT-OSA trial reported AHI reductions of up to 63% on tirzepatide 15 mg in participants with moderate-to-severe obstructive sleep apnea. 13 Comparable large-scale sleep-apnea data for semaglutide are not yet available.

Side-Effect Profiles: More Similar Than Different

Both drugs share a GLP-1 mechanism, so their adverse-effect profiles overlap substantially. Nausea, vomiting, diarrhea, and constipation are the most common complaints for both.

Gastrointestinal Events

In SURMOUNT-1, nausea occurred in 32.7% of tirzepatide 15 mg participants vs 16.7% placebo. 3 In STEP-1, nausea occurred in 44.2% of semaglutide 2.4 mg participants vs 16.3% placebo. 4 Direct comparison of these percentages is complicated by different dose-escalation schedules, but a 2024 network meta-analysis in Obesity Reviews found semaglutide 2.4 mg generated statistically more nausea than tirzepatide 15 mg on indirect comparison (OR 1.33, 95% CI 1.09 to 1.62). 14

Gallbladder Events

Rapid weight loss from any GLP-1 therapy increases cholelithiasis risk. In STEP-1, cholelithiasis occurred in 2.6% semaglutide vs 1.2% placebo. In SURMOUNT-1, gallbladder-related adverse events occurred in 1.8% on tirzepatide 15 mg vs 0.8% placebo. 3 The absolute rates are low for both drugs.

Injection-Site Reactions and Other Safety Signals

Both drugs are administered as subcutaneous injections once weekly. Tirzepatide's dual-agonist mechanism does not appear to create meaningful new adverse-effect categories beyond GLP-1 agents. The FDA's prescribing information for both Zepbound and Ozempic carries class-level warnings for medullary thyroid carcinoma risk based on rodent data, with neither drug contraindicated in the absence of a personal or family history of MEN2 or MTC. 15

Cost, Access, and Practical Selection Criteria

Efficacy is only one dimension of drug selection. Cost and insurance coverage shape real-world access for most patients.

List Price and Insurance Coverage

As of early 2025, Zepbound's list price is approximately $1,059/month and Ozempic's is approximately $936/month before insurance, though both manufacturers offer savings programs. Medicare covers Ozempic for T2D under Part D but does not cover Zepbound (or Wegovy) for obesity alone under Part D, a coverage gap that the Treat and Reduce Obesity Act aims to address but has not yet closed. 16

When Ozempic Is Clinically Preferred

Ozempic has a longer track record in T2D, more cardiovascular outcomes data (SELECT, SUSTAIN-6), and a larger real-world safety dataset. Clinicians at HealthRX typically consider semaglutide first for patients whose primary goal is cardiovascular risk reduction rather than maximal weight loss, or for patients who have prior documented tolerance of semaglutide from a previous prescription.

When Zepbound Is Clinically Preferred

Tirzepatide's stronger weight-loss signal makes it the preferred choice when the clinical goal is ≥15% weight reduction, when the patient has failed semaglutide at therapeutic doses, or when T2D glycemic targets have not been met on semaglutide. The ADA's 2024 Standards of Care state: "For patients with type 2 diabetes who require additional weight management, tirzepatide may be preferred given greater weight loss efficacy." 12

HealthRX Clinical Selection Framework: Zepbound vs Ozempic

| Clinical Priority | Preferred Agent | Supporting Trial | |---|---|---| | Maximum weight loss (≥15% target) | Tirzepatide (Zepbound) | SURMOUNT-1 | | Cardiovascular risk reduction (established CVD) | Semaglutide (Wegovy/Ozempic) | SELECT | | T2D glycemic control, HbA1c ≥8.5% | Tirzepatide (Mounjaro) | SURPASS-2 | | Prior semaglutide intolerance | Tirzepatide (Zepbound) | Class switch | | Cost or formulary constraint | Whichever is covered | N/A | | Obstructive sleep apnea comorbidity | Tirzepatide (Zepbound) | SURMOUNT-OSA |

What Switching Between Drugs Looks Like Clinically

Patients and clinicians do switch between these agents, either because of tolerability, formulary changes, or insufficient response.

Switching from Ozempic to Zepbound

No published pharmacokinetic bridging study exists for this specific switch. Given overlapping GLP-1 mechanisms and similar half-lives (roughly seven days for both), most published guidance recommends starting tirzepatide at 2.5 mg the week after the last semaglutide dose rather than attempting a dose-equivalent conversion. A 2023 guidance document from the Obesity Medicine Association notes that GLP-1 receptor agonist class switches should restart dose titration from the lowest available dose to minimize GI adverse effects. 17

Switching from Zepbound to Ozempic

Patients switching from tirzepatide to semaglutide should expect reduced weight-loss efficacy on average, based on the cross-trial efficacy data reviewed above. The clinical reason for such a switch is typically insurance-driven. In that scenario, the semaglutide dose is titrated from 0.25 mg weekly regardless of the tirzepatide dose the patient was on.

Monitoring After a Switch

After either switch direction, clinicians should recheck HbA1c at 12 weeks if the patient has T2D, and body weight at 8 and 16 weeks to determine whether the new agent is producing adequate response. The Endocrine Society's 2023 obesity pharmacotherapy guideline recommends defining therapeutic response as ≥5% body-weight loss at 12 to 16 weeks; absence of that threshold warrants dose escalation or reconsideration of the agent. 18

Pregnancy, Fertility, and Hormonal Considerations

Neither Zepbound nor Ozempic is approved for use in pregnancy. Both should be discontinued at least two months before a planned conception attempt, per FDA labeling. 15

Women with polycystic ovary syndrome (PCOS) may experience restored ovulation during GLP-1 therapy as body weight falls, which makes reliable contraception essential during treatment. This applies equally to tirzepatide and semaglutide. The American College of Obstetricians and Gynecologists' 2023 committee opinion on obesity management notes that GLP-1 receptor agonists may increase fertility in women with PCOS by improving insulin sensitivity and reducing androgen excess, and advises clinicians to counsel patients accordingly. 19

Long-Term Weight Maintenance: What Happens When You Stop

Both drugs require continued use to maintain weight loss. STEP-4 demonstrated that stopping semaglutide 2.4 mg after 20 weeks caused participants to regain roughly two-thirds of lost weight within 48 weeks of discontinuation. 20 Comparable discontinuation data for tirzepatide come from SURMOUNT-4, which showed that switching from tirzepatide to placebo after 36 weeks resulted in 14.8 percentage points of weight regain by week 88, while continued tirzepatide participants maintained their loss and added 5.5% more. 21

Both drugs appear to require indefinite use for maintained effect, a point the Obesity Medicine Association frames as consistent with treating obesity as a chronic disease rather than an acute condition. Prescribers should communicate this expectation to patients before initiating either therapy. 17